COVID-19 vaccines are indicated for active immunisation to prevent COVID-19 disease caused by the SARS-CoV-2 virus.
Short Overview Centrally Procured COVID-19 Vaccine ProductsSearch results 26 to 29 from a total of 29
| Name | Description | Marketing Authorisation Holder | Kind of Vaccine | License Number | License Date | Further Information |
|---|---|---|---|---|---|---|
Comirnaty KP.2 (30 µg) |
COVID-19-Impfstoff (mRNA) Verwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards |
BioNTech Manufacturing GmbH |
Mono | EU/1/20/1528 | 21.12.2020 | Zulassungserweiterung / EPAR: Comirnaty |
Comirnaty KP.2 (10 µg) |
COVID-19-Impfstoff (mRNA) Verwendung ab einem Lebensalter von 5 bis 11 Jahren / Use from 5 to 11 years of age |
BioNTech Manufacturing GmbH |
Mono | EU/1/20/1528 | 21.12.2020 | Zulassungserweiterung / EPAR: Comirnaty |
Comirnaty |
COVID-19-Impfstoff (mRNA) Verwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards |
BioNTech Manufacturing GmbH |
Mono | EU/1/20/1528 | 21.12.2020 | EPAR: Comirnaty Rote-Hand-Brief: BioNTech und Moderna zu den Impfstoffen Comirnaty und Spikevax (19.07.2021) |
Kostaive |
COVID-19-Impfstoff (sa-mRNA) Verwendung ab einem Lebensalter von 18 Jahren / Use from 18 years of age onwards |
Arcturus Therapeutics Europe B.V., Niederlande |
Mono | EU/1/24/1873 | 12.02.2025 |
The vaccine list contains the preparations that have a valid authorisation from the European Commission. It does not provide any information about whether the preparations are available on the market.
Updated: 06.12.2024
